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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER1661Consensus on Type B Aortic DissectionRossella Fattori, Piergiorgio Cao, Paola De Rango, Martin Czerny, Arturo Evangelista, Christoph Nienaber,
Hervé Rousseau, Marc Schepens
An expert multidisciplinary panel reviewed available literature to develop treatment algorithms
for type B aortic dissections. Patients were stratified based on time of presentation and the
presence of complications. Treatment options evaluated included medical management, open
surgery, or thoracic endovascular repair (TEVAR). Although limited by a lack of randomized
data and the nonconsistency of findings used to define complications, the panel suggests that
medical management with close imaging follow-up is the best strategy for uncomplicated type
B dissection with acute, subacute, and chronic presentation. TEVAR should be used for
complicated cases with suitable anatomy.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY1679Colchicine and RestenosisSpyridon Deftereos, Georgios Giannopoulos, Konstantinos Raisakis, Charalambos Kossyvakis, Andreas Kaoukis,
Vasiliki Panagopoulou, Metaxia Driva, George Hahalis, Vlasios Pyrgakis, Dimitrios Alexopoulos,
Antonis S. Manolis, Christodoulos Stefanadis, Michael W. Cleman
To avoid prolonged dual antiplatelet therapy, diabetic patients occasionally undergo
percutaneous coronary intervention (PCI) with bare-metal stent (BMS) placement.
Deftereos and colleagues test the hypothesis that colchicine treatment after PCI
using BMS can reduce the incidence of in-stent restenosis (ISR). A total of 222
diabetic patients undergoing PCI and BMS placement were randomized to colchicine
or placebo. Restenosis and neointima formation was studied at 6 months using
angiography and intravascular ultrasound (IVUS). Angiographic ISR rate was 16% in
the colchicine group versus 33% in the controls (p  0.007). IVUS-defined restenosis
rates were similarly reduced. The results show that colchicine is associated with reduced
ISR rates in diabetic patients after PCI with BMS.
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iACUTE CORONARY SYNDROMES1688Nonsystem Delays in D2BT and MortalityRajesh V. Swaminathan, Tracy Y. Wang, Lisa A. Kaltenbach, Luke K. Kim, Robert M. Minutello,
Geoffrey Bergman, S. Chiu Wong, Dmitriy N. Feldman
Swaminathan and colleagues sought to characterize nonsystem reasons for delay in door-to-
balloon time (D2BT) and impact on in-hospital mortality. A total of 82,678 ST-segment
elevation myocardial infarction (STEMI) patients who underwent primary percutaneous
coronary intervention (PCI) within 24 h of symptom onset were evaluated. Examples of
nonsystem delays include delays in obtaining consent, difficult vascular access, difficulties
crossing the culprit lesion, and a patient with cardiac arrest requiring intubation prior to PCI.
Nonsystem delays occurred in approximately 15% of patients and were more likely in older,
female, and African-American patients. The in-hospital mortality of patients treated without
delay was 2.5% versus 15.1% for those with delay. Despite shortest time delay, cardiac arrest/
intubation patients had the highest in-hospital mortality. The authors conclude that delay in
D2BT in STEMI patients are common and are associated with high in-hospital mortality.Editorial Comment: Cindy L. Grines, Theodore Schreiber, p. 1696CARDIOMETABOLIC RISK1698Obesity, Insulin Resistance, and LV Remodeling in the MESA TrialRavi V. Shah, Siddique A. Abbasi, Bobak Heydari, Carsten Rickers, David R. Jacobs, Jr, Lu Wang,
Raymond Y. Kwong, David A. Bluemke, Joao A. C. Lima, Michael Jerosch-Herold
Using the data from the MESA (Multi-Ethnic Study of Atherosclerosis), Shah and
colleagues tested whether insulin resistance and central obesity are associated with concentric
left ventricular (LV) remodeling independent of body mass index (BMI). A total of 4,364
individuals without diabetes but with impaired fasting glucose (IFG) or insulin resistance
(HOMA-IR) and waist-to-hip ratio were used for cardiometabolic phenotyping. LV
remodeling was assessed using cine magnetic resonance imaging. Results showed that in each
quartile of BMI, individuals with above-median HOMA-IR or an above-median WHR or
IFG had a higher LV mass to volume ratio (p  0.05). The authors demonstrate the
ssociation among insulin resistance, central obesity, and concentric LV remodeling
ndependent of BMI and metabolic risk factors.(continued on page A-22)
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EHEART RHYTHM DISORDERS1707Long-Term Outcomes After Cryoballoon AblationJürgen Vogt, Johannes Heintze, Klaus J. Gutleben, Bogdan Muntean, Dieter Horstkotte, Georg Nölker
In this prospective observational study, Vogt and colleagues report on the long-term outcomes
of cryoablation in patients with atrial fibrillation (AF) including effect of the size of
cryoballoon used. A total of 605 patients with symptomatic paroxysmal or persistent AF were
consecutively enrolled and followed for a median of 24 months. Rates of freedom from AF
with and without repeat ablation were 61.1% and 76.9%, respectively. Use of smaller balloon
size was associated with higher success rate. The authors conclude that long-term rates of
freedom from AF after cryoballoon ablation are similar to those of radiofrequency ablation,
however, further multicenter randomized trials are needed.Editorial Comment: Sabine Ernst, p. 1724HEART RHYTHM DISORDERS1713The STOP AF Pivotal TrialDouglas L. Packer, Robert C. Kowal, Kevin R. Wheelan, James M. Irwin, Jean Champagne,
Peter G. Guerra, Marc Dubuc, Vivek Reddy, Linda Nelson, Richard G. Holcomb, John W. Lehmann,
Jeremy N. Ruskin, for the STOP AF Cryoablation Investigators
The STOP AF pivotal trial by Packer and colleagues evaluates the safety and effectiveness of
a novel cryoablation technique in treating atrial fibrillation (AF) as compared to standard anti
arrhythmic therapy. A total of 245 patients with symptomatic paroxysmal AF and previously
failed therapy with 1 anti arrhythmic drug were randomized to cryoablation
(n  163) or anti arrhythmic therapy (n  82). A 12-month treatment success was seen in
9.9% of cryoablation patients as compared to 7.3% of anti arrhythmic drug patients. Of the
ryoablated patients, a total of 3.1% and 11.2% developed PV stenosis and phrenic nerve
alsy, respectively. Most phrenic nerve palsy resolved at 1 year. The study concluded that
ryoballoon ablation is a safe and effective alternative to anti arrhythmic therapy.
ditorial Comment: Sabine Ernst, p. 1724(continued on page A-26)
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Weight GainAlan Maisel, Denise Barnard, Brian Jaski, Geir Frivold, John Marais, Maged Azer, Michael Miyamoto,
Dawn Lombardo, Damon Kelsay, Kelly Borden, Navid Iqbal, Pam R. Taub, Ken Kupfer, Paul Clopton,
Barry Greenberg
In this multicenter, single-arm, double-blinded, observational, prospective trial, using a novel
finger test, Maisel and colleagues evaluated whether daily home B-type natriuretic peptide
(BNP) testing correlated with acute clinical heart failure decompensation (ADHF) and
related adverse clinical outcomes in at-risk heart failure patients. A total of 163 patients with
ADHF discharged from the hospital or in an outpatient setting measured weight and daily
BNP test for 60 days with a finger-stick test. Correlation between BNP measures weakened
over time and dispersion between BNP measures grew. The BNP levels were useful in
identifying patients with ADHF. The authors conclude that home BNP testing is feasible.
Daily weight monitoring is complimentary to BNP, but BNP changes correspond to larger
changes in upward or downward risk.VASCULAR DISEASE1736Advanced Age and Vascular Disease TerritoriesNazir Savji, Caron B. Rockman, Adam Skolnick, Yu Guo, Mark A. Adelman, Thomas Riles, Jeffrey S. Berger
To better understand the relationship between advanced age and peripheral vascular disease
(PVD), Savji and colleagues examined data from 3.6 million self-referred participants. Data
was provided by Life Line Screening, Inc., and included demographics, lifestyle, ankle
brachial index (ABI), ultrasound for carotid artery imaging (CAS), and abdominal aortic
aneurysm (AAA). Overall incidence for peripheral vascular disease (PVD) was increased with
age and was 7.48% (PAD: 3.7%, CAS: 3.9%, AAA: 0.9%). Based on this large database, the
authors conclude that PVD is common and strongly associated with chronological age.
